$ News

Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

iTeos Therapeutics (ITOS): An Example of Biotech Liquidations

iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure

iTeos Therapeutics Announces Its Intention to Wind Down Operations

Cancer drugmaker iTeos to shut down

GSK and iTeos drop anti-TIGIT drug following trial failure

iTeos Therapeutics: TIGIT Falls, And A Zombie Rises?

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile

GSK, iTeos Therapeutics End Belrestotug Development Program

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet

iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates